KR101925971B1 - 피리돈 유도체 및 이를 포함하는 약학적 조성물 - Google Patents

피리돈 유도체 및 이를 포함하는 약학적 조성물 Download PDF

Info

Publication number
KR101925971B1
KR101925971B1 KR1020120008536A KR20120008536A KR101925971B1 KR 101925971 B1 KR101925971 B1 KR 101925971B1 KR 1020120008536 A KR1020120008536 A KR 1020120008536A KR 20120008536 A KR20120008536 A KR 20120008536A KR 101925971 B1 KR101925971 B1 KR 101925971B1
Authority
KR
South Korea
Prior art keywords
azabicyclo
oxo
pyridinecarboxamide
octan
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020120008536A
Other languages
English (en)
Korean (ko)
Other versions
KR20120087852A (ko
Inventor
맹철영
장용구
차수봉
신혜원
정찬미
차화륜
이은정
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20120087852A publication Critical patent/KR20120087852A/ko
Application granted granted Critical
Publication of KR101925971B1 publication Critical patent/KR101925971B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020120008536A 2011-01-28 2012-01-27 피리돈 유도체 및 이를 포함하는 약학적 조성물 Active KR101925971B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020110008960 2011-01-28
KR20110008960 2011-01-28

Publications (2)

Publication Number Publication Date
KR20120087852A KR20120087852A (ko) 2012-08-07
KR101925971B1 true KR101925971B1 (ko) 2018-12-06

Family

ID=46581019

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120008536A Active KR101925971B1 (ko) 2011-01-28 2012-01-27 피리돈 유도체 및 이를 포함하는 약학적 조성물

Country Status (8)

Country Link
US (1) US8716309B2 (https=)
EP (1) EP2668186B1 (https=)
JP (1) JP5921576B2 (https=)
KR (1) KR101925971B1 (https=)
CN (1) CN103328477B (https=)
CA (1) CA2824467C (https=)
ES (1) ES2634204T3 (https=)
WO (1) WO2012102580A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101928505B1 (ko) 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
EP3259262A4 (en) * 2015-02-17 2018-08-01 Mapi Pharma Limited Process and intermediates for the preparation of perampanel
AR107928A1 (es) 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
WO2019028062A1 (en) * 2017-07-31 2019-02-07 Washington University PIRFENIDONE DERIVATIVES FOR MODULATION OF B-LYMPHOCYTE ACTIVITY AND PROTECTION OF ORGANS
RS66290B1 (sr) 2018-05-01 2025-01-31 Merck Sharp & Dohme Llc Spiropiperidin alosterični modulatori nikotinskih acetiholinskih receptora
CN109293507B (zh) * 2018-10-12 2020-12-18 河北科技大学 4-甲氧基甲烯基-2-烯戊二酸二甲酯的合成方法及其应用
EP4054569A4 (en) 2019-11-05 2023-10-25 Merck Sharp & Dohme LLC ALLOSTERIC SPIROPIPERIDINE MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTORS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020568A1 (en) 2002-01-07 2005-01-27 Frederic Galli Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404138A (en) * 1982-06-22 1983-09-13 Warner-Lambert Company 3-[2-(Azabicyclo) ethyl]-1,2,3,4-tetrahydro-5H-[1]benzopyrano[3,4-c]pyridin-5-ones
TR200102162T2 (tr) * 1999-01-29 2001-12-21 Abbott Laboratories Nikotinik asetilkolin reseptör ligandları olarak diazabisiklik türevler.
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6569865B2 (en) * 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
AU2002339810A1 (en) * 2001-10-16 2003-04-28 Astrazeneca Ab Azabicyclic compounds for the treatment of fibromyalgia syndrome
EP2344636B1 (en) * 2008-10-09 2017-12-06 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
US20110262407A1 (en) * 2008-11-11 2011-10-27 Targacept, Inc. Treatment with alpha7 selective ligands
KR101928505B1 (ko) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 피리돈 유도체 및 이를 포함하는 약학적 조성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050020568A1 (en) 2002-01-07 2005-01-27 Frederic Galli Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics

Also Published As

Publication number Publication date
EP2668186B1 (en) 2017-05-03
ES2634204T3 (es) 2017-09-27
EP2668186A1 (en) 2013-12-04
US20130317059A1 (en) 2013-11-28
JP2014503599A (ja) 2014-02-13
CN103328477B (zh) 2016-01-20
CA2824467C (en) 2019-07-02
US8716309B2 (en) 2014-05-06
KR20120087852A (ko) 2012-08-07
CN103328477A (zh) 2013-09-25
JP5921576B2 (ja) 2016-05-24
EP2668186A4 (en) 2014-03-19
CA2824467A1 (en) 2012-08-02
WO2012102580A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
KR101925971B1 (ko) 피리돈 유도체 및 이를 포함하는 약학적 조성물
AU784400B2 (en) New use and novel N-azabicyclo-amide derivatives
JP4497928B2 (ja) α７ニコチン性アセチルコリン受容体に対して親和性を有する１−アザビシクロＮ−ビアリールアミド
CA2467367C (en) Heteroaryl carboxamides
JP4690651B2 (ja) 二環式ｎ−アリールアミド類
KR102034305B1 (ko) 피리돈 유도체 및 이를 포함하는 약학적 조성물
JPH01151576A (ja) 老人性痴呆症の治療用オキサゾール及びチアゾール
JP2005526777A (ja) 酢酸およびプロピオン酸のアミド類
JP4813357B2 (ja) Ｎ−ビアリールアミド化合物
HK1187336B (en) Pharmaceutical composition comprising pyridone derivatives

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 20120127

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170116

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 20120127

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180328

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20180928

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20181130

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20181130

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20211103

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20211103

Start annual number: 4

End annual number: 4

FPAY Annual fee payment

Payment date: 20220906

Year of fee payment: 5

PR1001 Payment of annual fee

Payment date: 20220906

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20230904

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240911

Start annual number: 7

End annual number: 7